← Evidence map

TrialRheumatology (Oxford, England)2026

Bimekizumab efficacy in male and female patients with axial spondyloarthritis: 52-week results from the phase 3 BE MOBILE trials.

Martin Rudwaleit et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

2 trials

NCT03928704phase 3274 enrolled2019 NCT03928743phase 3332 enrolled2019

Bimekizumab efficacy in male and female patients with axial spondyloarthritis: 52-week results from the phase 3 BE MOBILE trials. | OpenQuestion